PMID- 26206530
OWN - NLM
STAT- MEDLINE
DCOM- 20160615
LR  - 20181113
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Print)
IS  - 0950-222X (Linking)
VI  - 29
IP  - 11
DP  - 2015 Nov
TI  - Evaluating the impact of summer vacation on the visual acuity of AMD patients 
      treated with ranibizumab.
PG  - 1453-7
LID - 10.1038/eye.2015.128 [doi]
AB  - PURPOSE: To evaluate the impact of traditional French summer vacation on visual 
      acuity and spectral domain-optical coherence tomography (SD-OCT) of Wet AMD 
      patients being treated with intravitreal Ranibizumab. METHODS: This was a 
      consecutive, comparative, single-centre, prospective analysis. All patients who 
      were being treated with intravitreal injection of 0.5 mg ranibizumab at Cergy 
      Pontoise Hospital, Department of Ophthalmology between July 2013 and September 
      2014 were included. Patients were divided into two groups: (A) patients who 
      skipped one ranibizumab intravitreal injection during holidays, and (B) patients 
      who received injection during their holidays. Evaluations occurred prior to 
      traditional holiday (baseline) and 2 months later, consisting of BCVA using 
      ETDRS, and a complete ophthalmic examination that included slit-lamp 
      biomicroscopy, fundus examination, fluorescein angiography (FA), indocyanine 
      green angiography (ICGA), and spectral domain-optical coherence tomography 
      (SD-OCT). All patients were being treated with PRN anti-VEGF regimen and criteria 
      for reinjection included a visual acuity loss >5 ETDRS letters and/or an increase 
      of central retinal thickness, presence of subretinal fluid, intraretinal fluid, 
      or pigment epithelium detachment. If reinjection criteria were not met, patients 
      were advised to return in 4 weeks. RESULTS: The mean visual acuity change was 
      -0.071 +/- 0.149 (LogMAR) in group A and + 0.003 +/- 0.178 in group B (P = 0.041). At 
      the second visit (2 months after preholidays visit), 61.8% of patients in group A 
      had SRF and/or intraretinal cysts, and only 27.6% of patients in group B. There 
      was a significant difference in the persistence of fluid between the two groups 
      (P = 0.007, chi(2)-test). CONCLUSION: This cases series demonstrated the 
      detrimental impact of holidays on visual acuity in patients treated with 
      ranibizumab for AMD, which, in spite of their treatment regimen, still leave in 
      vacation. Therefore, it is important to convey the message of treatment adherence 
      to patients, despite their need of holidays.
FAU - Massamba, N
AU  - Massamba N
AD  - Department of Ophthalmology, Cergy Pontoise Hospital, Paris, France.
FAU - Dirani, A
AU  - Dirani A
AD  - Department of Ophthalmology, CHUV, Lausanne, Switzerland.
FAU - Knoeri, J
AU  - Knoeri J
AD  - Department of Ophthalmology, Cergy Pontoise Hospital, Paris, France.
FAU - Pasquier, B
AU  - Pasquier B
AD  - Department of Ophthalmology, Cergy Pontoise Hospital, Paris, France.
FAU - Ingram, A
AU  - Ingram A
AD  - Department of Ophthalmology, April Ingram Research Consultants, Kelowna, British 
      Columbia, Canada.
FAU - Soubrane, G
AU  - Soubrane G
AD  - Department of Ophthalmology, Hotel Dieu Hospital, Paris V University, Paris, 
      France.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20150724
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Female
MH  - Fluorescein Angiography
MH  - *Holidays
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - *Medication Adherence/statistics & numerical data
MH  - Patient Compliance
MH  - Prospective Studies
MH  - Ranibizumab/*therapeutic use
MH  - Retreatment
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/*physiology
MH  - Wet Macular Degeneration/*drug therapy/physiopathology
PMC - PMC4815657
EDAT- 2015/07/25 06:00
MHDA- 2016/06/16 06:00
PMCR- 2016/11/01
CRDT- 2015/07/25 06:00
PHST- 2014/10/17 00:00 [received]
PHST- 2015/06/08 00:00 [accepted]
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2016/06/16 06:00 [medline]
PHST- 2016/11/01 00:00 [pmc-release]
AID - eye2015128 [pii]
AID - 10.1038/eye.2015.128 [doi]
PST - ppublish
SO  - Eye (Lond). 2015 Nov;29(11):1453-7. doi: 10.1038/eye.2015.128. Epub 2015 Jul 24.